Applying Ocado, the UPC grants a R262 request to access CFI documents

​
July 9, 2025

NJOY Netherlands B.V v Juul Labs International, Inc (UPC_CFI_309/2023)

Order issued 9 June 2025 (ORD_27305/2025) [1]

The Paris Central Division revoked Juul Lab's patent EP 3 498 115 B1 by decision dated 5th November 2024 (UPC CFI 309 /2023). [2] Juul Labs subsequently appealed the decision, and while the appeal remains pending, a firm of lawyers and patent attorneys ("the Applicant") lodged a request under Rule 262.1(b) on 21 February 2025 to access pleadings and evidence in the first instance proceedings. Juul Labs requested that the Court rejects the request, and alternatively, if the Court does grant the request, it should grant access only with a restriction ‘from filing the written pleadings or parts of them with other courts or judicial instances.'

The Law

Rule 262.1(b) states that written pleadings and evidence lodged at the Court and recorded by the Registry shall be available to the public upon ‘reasoned request' to the Registry; the decision is taken by the judge-rapporteur after consulting the parties. A ‘reasoned request' is one where an applicant explains why their access to the specified documents is necessary and legitimate. A party to the litigation may request that certain information in written pleadings or evidence be kept confidential and provide specific reasons for such confidentiality.

The Court of Appeal in Ocado v Autostore (UPC_CoA_404/2023)[3] expanded on Rule 262, finding that when there is a request made by a member of public to access court documents, the interests of a member of the public must be weighed against the interests mentioned in Articles 10 and 45 UPCA. Articles 10 and 45 govern the general principle that first instance and appeal proceedings shall be open to the public unless the Court decides to make them confidential, to the extent necessary, in the interest of one of the parties or other affected persons, or in the general interest of justice or public order.

The Applicant's interest

The Applicants' interest is one of access to precedent. As a German IP firm, they submit that they represent various clients in revocation proceedings before the UPC which have ‘comparable subject matter' to the first instance decision. For this reason, they argue their request is justified because they intend to obtain a ‘comprehensive picture of the line of arguments that led to the Court's decision' (para 3.7).

The Defendant's interest

Juul Labs argued that, despite their claim to represent other UPC parties in revocation cases with ‘comparable subject matter,' the Applicant has no legitimate interest in the subject matter of the present case. Juul Labs alleged that the Applicant would likely ‘copy-paste' extracts from the written pleadings and evidence to reproduce into EPO oppositions or other court proceedings, leading to third party access of such material without lodging a reasoned request with the UPC, thereby contravening the interests of the parties and the UPCA principles to keep relevant materials confidential.

Decision

Per Ocado v Autostore, the Court must undergo a weighing of the balance of interests. The Court found that the Applicant had submitted a reasonable request; their intention to obtain a greater understanding of the arguments that led to the Court's decision was justifiable. The Court did not find Juul Labs' arguments to be capable of shifting the balance of interest towards withholding the case documents, and the Court found their denouncement of the Applicant's legitimate interest insufficient. Juul Labs' concerns about the potential misuse of documents in other jurisdictions were also dismissed. The Court clarified that the general position as found in Articles 10 and 45 is that ‘the register is public and proceedings are open to the public, unless the balance of interest involved is such that they are to be kept confidential' (para 4.4). Quoting Ocado v Autostore (para 50), the Court clarified that withholding access to documents once a judgment has been published no longer serves the purpose of protecting the integrity of proceedings, as the publicly available decision will contain the relevant arguments and evidence presented by the parties and thus already subject to public debate.

The Court granted the Applicant access to written pleadings and evidence, with appropriate redaction of personal data. However, the Court also granted Juul Labs leave to appeal and suspended the effects of the order until the deadline for filing an appeal, or if an appeal is filed, until the end of the appeal proceedings.

Written by Dalton Tucker and Fathia Adeniran.

[1] https://www.unified-patent-court.org/en/node/125754

[2] https://www.unified-patent-court.org/en/node/1239

[3] https://www.unified-patent-court.org/en/node/657

The Latest Thought Leadership pieces in the Content Hub

No items found.
Stay in the Know

The Patent Strategist

Get expert insights and the top patent stories delivered straight to your inbox.

Heading
This is some text inside of a div block.
This is some text inside of a div block.

Latest Insights

Showing 0 of 100
Is Your AI Conversation Privileged?
08 May 2026
Recent US court decisions have, for the first time, tested whether conversations with AI tools can be protected by legal privilege. In United States v. Heppner, a court held that documents generated by a defendant using a public AI platform were not protected by attorney‑client privilege, largely because the AI was not used within a lawyer‑directed relationship and the platform’s terms allowed data retention and disclosure. By contrast, in Warner v. Gilbarco, another court found that AI‑assisted materials created by a self‑represented litigant were protected under the work‑product doctrine, which has a more forgiving standard for waiver.
#
Consulting
​
The evolution of nucleic acid sequencing and what it means for Genomics and IP
27 April 2026
This article outlines the evolution of nucleic acid sequencing, from early Sanger methods to next‑generation and long‑read technologies. The journey from deciphering individual DNA strands to sequencing entire genomes in hours represents one of biotechnology's most impressive transformations. The first human genome, completed through the Human Genome Project, took around 13 years to sequence and cost billions of dollars, whereas modern sequencing methods can now deliver a genome in hours for a few hundred dollars. For those interested in patents and life sciences, understanding the technical evolution of sequencing methods offers insights into how fundamental scientific advances translate into valuable patent portfolios.
#
Consulting
​
World IP Day: The big ideas shaping IP's fastest-moving fields
24 April 2026
For World IP Day, we asked experts of EIP’s five growth areas: Uniphy, Ampliphy, Stratiphy, Codiphy and Quantiphy, to share a quick insight on innovation, IP trends, and what excites them about the future. Each responded to a single, focused question reflecting the role their team plays across EIP.
#
Consulting
​
Meet the EIP team heading to INTA 2026 in London
23 April 2026
INTA's Annual Meeting is coming to London. From 2–6 May 2026, the ExCeL will host more than 10,000 trade mark and IP professionals from over 100 jurisdictions — five days of sessions, side events, and the kind of corridor conversations that turn into lasting working relationships.
#
Litigation
​
Antibody Patent Protection in Europe and the US: Navigating EPO and USPTO Differences
16 April 2026
This article explores the complexities of patenting antibody therapies, focusing on the differing requirements and practices of the European Patent Office (EPO) and the United States Patent and Trademark Office (USPTO). It highlights how the scope of claims, inventiveness standards, and supporting data requirements vary between jurisdictions, and explains why a tailored IP strategy is essential for innovators especially SMEs seeking protection in both Europe and the US. The article also outlines how EIP’s transatlantic teams collaborate to optimise patent applications for success in these key markets.
#
Patenting
​
Why competitor patent monitoring is critical to your drug development strategy
15 April 2026
This article explains why competitor IP monitoring is a critical part of an effective drug development strategy. By tracking competitor patent activity, companies can assess freedom to operate, identify risks and opportunities early, and make informed decisions on patent filings, licensing, and investment readiness. Ongoing monitoring also supports FTO analysis, third‑party observations, oppositions, and litigation strategy, helping life sciences businesses protect value and reduce risk throughout development.
#
Consulting
​
Biopharma Strategy in 2026: Lessons from 2025 on AI, M&A and the UPC
13 April 2026
This article looks back on a selection of key trends in the (bio)pharma industry in 2025 and looks ahead to how these may continue to develop into 2026.
#
Consulting
​
Thinking about IP from day one: strategic considerations for deep tech startups
08 April 2026
For deep tech startups, intellectual property decisions often come too late or cost too much too soon. This article explores why IP strategy should be considered from day one, even if formal protection comes later. It outlines how founders can decide what to patent, when trade secrets may be more appropriate, and how detectability, enforceability and cost should shape early choices. With a focus on practicality and commercial alignment, it also looks at how newer, AI‑assisted approaches can help startups take a more cost‑effective and flexible approach to building meaningful IP protection.
#
Consulting
​
National offices report increases in national patent applications throughout Europe: Is the EPO no longer “killing” the national offices?
27 March 2026
National patent offices across Europe have reported a marked increase in patent filings in 2025, breaking with a long‑standing downward trend. Data from Germany, France, Italy, Sweden, Austria, Spain and Norway point to growing activity driven by digital technologies, electrification and increased university participation. At the same time, offices report a rise in self‑drafted and AI‑assisted applications, which may lower barriers to entry but also raise concerns about application quality and examination efficiency.
#
Patenting
​
Make your bio(pharma) IP investment ready
22 March 2026
This recap of our LinkedIn Live series focuses on helping (bio)pharma businesses make their IP investment‑ready. Across three sessions, experts will discuss building resilient IP portfolios, making strategic IP decisions ahead of funding rounds, and what the evolving 2026 (bio)pharma landscape means for long‑term IP strategy.
#
Patenting
​
Are professional guidelines making Patent Attorneys too cautious on AI?
19 February 2026
As AI use accelerates in patent practice, many European patent attorneys remain cautious due to professional AI guidelines from the epi. This article argues those guidelines are not a barrier, but a baseline for responsible use.
#
Patenting
​
Provisional Agreement Reached on the EU Pharma Package: Takeaways for Pharmaceutical Companies
17 February 2026
The EU’s new Pharma Package will overhaul regulatory exclusivity, orphan drug incentives, antimicrobial innovation, and generic entry pathways, reducing standard protection periods while introducing new rewards like transferable exclusivity vouchers.
#
Patenting
​
Beyond CRISPR: Precision to Platform
23 January 2026
Gene editing is entering a new phase, moving beyond CRISPR-Cas9’s breakthrough but costly, bespoke therapies toward more precise and scalable platforms. While CRISPR-based treatments like Casgevy have proven clinical success, they remain expensive and entangled in ongoing patent disputes over foundational IP. Next-generation tools such as base editing and prime editing avoid double-strand DNA breaks, enabling more accurate corrections and broader therapeutic potential. The field’s focus is now shifting to disease-agnostic platforms that can be adapted across many conditions, improving access and efficiency.
#
Patenting
​
Confidentiality at the UPC: What litigants need to know
21 January 2026
This article explains how the Unified Patent Court approaches confidentiality in litigation, outlining the procedures for restricting access to sensitive information, how confidentiality clubs are formed, and when hearings may be held in private. It highlights key case law shaping these rules, the balance between fair trial rights and protection of commercial data, and the penalties for breaches. Practical guidance is provided to help parties navigate applications, manage confidential documents, and understand what to expect throughout UPC proceedings.
#
Litigation
​
EPO fees are going up in April 2026: Plan ahead now
19 January 2026
The European Patent Office will introduce a fee increase of roughly 5% from 1 April 2026, affecting search, examination, designation and renewal fees. Filing, excess page, opposition and appeal fees remain unchanged. Some costs—such as renewal fees—can be paid up to three months early, allowing applicants to secure the current lower rates. EIP recommends reviewing your portfolio ahead of the deadline.
#
Patenting
​